ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Seattle AVM Announces Second IND for AVM0703 for COVID-19, Influenza ARDS americanpharmaceuticalreview
September 23, 2020AVM Biotechnology has received U.S. Food and Drug Administration (FDA) permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza ...
Pharma Sources Insight January 2025
